A chalcone-modified triazinepropiconazole, its preparation method and application
Chalcone-modified triazine propiconazole solves the problems of insufficient permeability and antibacterial activity of existing propiconazole compounds, achieving highly efficient control of plant diseases with minimal impact on crops.
Patent Information
- Application Number
- CN202611357250.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-03
- Publication Date
- 2026-11-17
AI Technical Summary
Existing propiconazole compounds have low drug penetration and antibacterial activity, making them difficult to effectively control plant diseases.
Chalcone was used to modify propiconazole with triazone as a linking group to form a dual pharmacophore structure, which synergistically enhances antibacterial activity and improves drug penetration and antibacterial activity.
It enhances the dual interference ability against fungal cell membranes and cell walls, improves drug penetration and antibacterial activity, significantly improves the control effect on plant diseases, and reduces the impact on crops.
Smart Images

Figure CN123106683A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of chemical pharmaceutical synthesis technology, and in particular to a chalcone-modified triazinepropiconazole, its preparation method, and its application. Background Technology
[0002] Propiconazole is a systemic triazole fungicide with protective and curative effects. It inhibits the biosynthesis of ergosterol on the fungal cell membrane, thereby disrupting the structure and function of the fungal cell membrane and inhibiting its growth and reproduction. It has strong fungicidal activity and can effectively control fungal diseases of various crops, such as wheat rust, powdery mildew, and root rot; rice bakanae disease and sheath blight; banana leaf spot; and grape powdery mildew and anthracnose.
[0003] Propiconazole is a molecule with a triazole ring as its core, and its structure also contains a benzene ring and a cyclopropane side chain. Its structure has many modifiable sites, such as the substitution of nitrogen atoms on the triazole ring, the modification of double bonds in the ring, the adjustment of benzene ring substituents, or the introduction of other functional groups.
[0004] Chinese patent application CN 113234066 A discloses a propiconazole-like compound, its preparation method, and its application. The propiconazole-like compound has a structure similar to propiconazole. It is prepared by heating acetophenone compounds, alcohol compounds, and p-toluenesulfonic acid in toluene under reflux, followed by reaction with 1,2,4-triazole, anhydrous potassium carbonate, and DMAP. It exhibits bactericidal activity and shows good inhibition rates against *Fusarium graminearum*, *Brachystomata var. chinensis*, *Brachystomata var. chinensis*, *Anthracnose causal agent*, *Bacillus thuringiensis*, *Bacillus oryzae*, *Fusarium wilt*, *Rhizoctonia solani*, and *Sclerotinia sclerotinia* at a concentration of 50 ppm. Chinese patent application CN 1923838 A discloses propiconazole metal complexes, their preparation methods, and uses. This technical solution involves reacting propiconazole and a metal salt in a suitable solvent to obtain a solid propiconazole metal complex, which exhibits good sustained-release properties and significantly higher toxicity against plant pathogenic fungi than its ligand propiconazole, while showing lower inhibitory effects on seed germination and plant growth compared to the ligand propiconazole. However, propiconazole compounds prepared using existing technologies have lower drug permeability and antibacterial activity. Summary of the Invention
[0005] The purpose of this invention is to provide a chalcone-modified triazine propiconazole, its preparation method and application. Chalcone is used to modify propiconazole by using triazine acid as a linking group to improve drug permeability and antibacterial activity.
[0006] To achieve the above objectives, the present invention provides a chalcone-modified triazinepropiconazole, the structural formula of which is shown below:
[0007] .
[0008] This invention also provides a method for preparing chalcone-modified triazinepropiconazole, comprising:
[0009] Step S1: Disperse triazinon acid and chalcone in glacial acetic acid, add ammonium acetate, react to obtain the first intermediate reaction solution, add ammonia and water, filter to obtain the crude product of the first intermediate, and after washing and drying, obtain the first intermediate.
[0010] Step S2: The first intermediate is mixed with 1,4-dibromobutane and added to a solvent. A neutralizing agent is added, and the mixture is reacted and filtered to obtain the crude product of the second intermediate. The crude product of the second intermediate is washed and dried to obtain the second intermediate.
[0011] Step S3: Disperse propiconazole in a solvent, add an alkaline solution, and react to obtain the crude product of the third intermediate. After column chromatography and drying, the crude product of the third intermediate is obtained.
[0012] In step S4, the second and third intermediates are dispersed in a solvent, a catalyst is added, and the reaction yields a crude product of chalcone-modified triazinepropiconazole. After recrystallization and drying, the crude product of chalcone-modified triazinepropiconazole is obtained.
[0013] Preferably, in step S1, the reaction temperature is 100~120℃ and the reaction time is 6~8 h.
[0014] Preferably, in step S1, the amount of ammonia added is 1 to 3 times the mass of the solvent.
[0015] Preferably, in step S1, the amount of water added is 1 to 1.5 times the mass of the ammonia water.
[0016] Preferably, in step S1, the washing solvent is ammonia and water.
[0017] Preferably, in step S1, the drying temperature is 60~70℃ and the drying time is 8~10 h.
[0018] Preferably, in step S1, the mass ratio of triazinic acid, chalcone, ammonium acetate, and solvent is 1:(0.45~0.65):(2~3):(3~5).
[0019] Preferably, the solvent is any one or more of N,N'-dimethylformamide and dimethyl sulfoxide.
[0020] Preferably, in step S2, the neutralizing agent is any one or more of sodium bicarbonate and potassium carbonate.
[0021] Preferably, in step S2, the reaction temperature is 80~100℃ and the reaction time is 4~6 h.
[0022] Preferably, in step S2, the mass ratio of the first intermediate, 1,4-dibromobutane, neutralizing agent and solvent is 1:(1.1~1.5):(0.1~0.5):(3~5).
[0023] Preferably, in step S2, the drying temperature is 50~60℃ and the drying time is 8~10 h.
[0024] Preferably, in step S3, the alkaline solution is any one or more of sodium hydroxide aqueous solution and potassium hydroxide aqueous solution, wherein the mass ratio of water to sodium hydroxide in the sodium hydroxide aqueous solution is 1:(0.15~0.5), and the mass ratio of water to potassium hydroxide in the potassium hydroxide aqueous solution is 1:(0.15~0.5).
[0025] Preferably, in step S3, the mass ratio of propiconazole, alkaline solution, and solvent is 1:(0.1~0.3):(2~3).
[0026] Preferably, in step S3, the reaction temperature is 80~100℃ and the reaction time is 4~5 h.
[0027] Preferably, in step S3, the mobile phase for column chromatography is petroleum ether and ethyl acetate, and the volume ratio of petroleum ether to ethyl acetate is (5~8):1.
[0028] Preferably, in step S3, the drying temperature is 50~60℃ and the drying time is 8~10 h.
[0029] Preferably, in step S4, the catalyst is any one or more of sodium hydroxide, potassium hydroxide, and triethylamine.
[0030] Preferably, in step S4, the mass ratio of the second intermediate, the third intermediate, the catalyst, and the solvent is 1:(0.5~0.6):(0.2~0.5):(3~5).
[0031] Preferably, in step S4, the recrystallization solvent is methanol.
[0032] Preferably, in step S4, the reaction temperature is 80~100℃ and the reaction time is 5~8 h.
[0033] Preferably, in step S4, the drying temperature is 40~50℃ and the drying time is 8~10 h.
[0034] The present invention also provides the application of chalcone-modified triazinepropiconazole in bactericidal drugs.
[0035] Compared with the prior art, the beneficial effects of the present invention are reflected in:
[0036] (1) This invention uses chalcone to modify propiconazole with triazine as a linking group, forming a dual pharmacophore structure for synergistic antibacterial action. Propiconazole targets the C-14 demethylase in the ergosterol biosynthesis pathway of fungal cell membranes. By inhibiting the activity of this enzyme, it blocks ergosterol synthesis, leading to cell membrane structure destruction and loss of function, ultimately causing fungal death. The α,β-unsaturated ketone structure in the chalcone structure binds to β-1,3-glucan synthase in the fungal cell wall, inhibiting the synthesis of key cell wall components and interfering with the integrity of the fungal cell membrane. It can also enhance the killing effect on bacteria by inhibiting bacterial DNA topoisomerase or inducing the accumulation of reactive oxygen species in the cell. The triazine-propiconazole structure modified with chalcone maintains the inhibitory effect of propiconazole on ergosterol synthesis, and chalcone also endows the compound with the ability to interfere with both cell wall synthesis and membrane function.
[0037] (2) This invention uses chalcone and modifies propiconazole with triazine as a linking group to improve drug permeability and enhance antibacterial activity. The hydrophobic aromatic ring structure of chalcone can be embedded in the phospholipid bilayer of bacterial cell membrane, changing membrane fluidity and increasing membrane permeability, making it easier for propiconazole to enter the cell and exert its effect. The introduction of triazine may promote the diffusion of the drug in the biomembrane by reducing the molecular surface energy, thereby improving the permeation efficiency. Attached Figure Description
[0038] Figure 1 This is the synthetic route for the second intermediate.
[0039] Figure 2 This is the synthetic route for the third intermediate.
[0040] Figure 3 The synthetic route for chalcone-modified triazinepropiconazole. Detailed Implementation
[0041] The following embodiments are only used to illustrate the technical solutions of the present invention more clearly, and should not be used to limit the scope of protection of the present invention.
[0042] The compounds used in the examples and comparative examples were all commercially available products and were not subjected to any further purification treatment.
[0043] The Rhizoctonia cerealis used in the experiments was purchased from Wuhan Huana Biotechnology Co., Ltd.
[0044] The Rhizoctonia solani used in the experiments was purchased from Nuoan Gene Technology (Wuhan) Co., Ltd.
[0045] The culture medium used in the experiment was PDA liquid medium, with the following formula: potato (peeled) 200 g / L.
[0046] Dissolve 20 g / L glucose in distilled water, bring the volume to 1 L, autoclave at 121℃ for 15 min, and set the pH to 5.6±0.2.
[0047] The culture medium used in the experiment was PDA solid culture medium, with the following formula: 15 g of agar powder was added to the liquid culture medium, and the volume was adjusted to 1 L with distilled water. The medium was then autoclaved at 121℃ for 15 min, and the pH was 5.6±0.2.
[0048] Example 1
[0049] like Figure 1 As shown, a chalcone-modified triazinepropiconazole is prepared by a method comprising:
[0050] Step S1: Disperse 10 g of triazinic acid and 4.5 g of chalcone in 30 g of glacial acetic acid, add 20 g of ammonium acetate, react at 100 °C for 8 h to obtain the first intermediate reaction solution, add 30 g of ammonia and 45 g of water, filter to obtain the crude product of the first intermediate, wash the crude product of the first intermediate with ammonia and water respectively, and dry at 60 °C for 10 h to obtain the first intermediate.
[0051] Step S2: 10 g of the first intermediate and 11 g of 1,4-dibromobutane were mixed and added to 30 g of N,N'-dimethylformamide. 1 g of sodium bicarbonate was added, and the mixture was reacted at 80°C for 6 h. The reaction was filtered to obtain the crude product of the second intermediate. The crude product of the second intermediate was washed with water and dried at 50°C for 10 h to obtain the second intermediate, as shown below. Figure 1 As shown.
[0052] Step S3: 10 g of propiconazole was dispersed in 20 g of N,N'-dimethylformamide, and 1 g of sodium hydroxide aqueous solution (0.13 g of sodium hydroxide and 0.87 g of water) was added. The mixture was reacted at 80 °C for 5 h to obtain the crude product of the third intermediate. The crude product of the third intermediate was subjected to column chromatography with a mixture of 500 mL of petroleum ether and 100 mL of ethyl acetate as the mobile phase, and then dried at 50 °C for 8 h to obtain the third intermediate. Figure 2 As shown.
[0053] Step S4: 10 g of the second intermediate and 5 g of the third intermediate were dispersed in 30 g of N,N'-dimethylformamide, and 2 g of sodium hydroxide was added. The mixture was reacted at 80 °C for 8 h to obtain a crude chalcone-modified triazinepropiconazole product. The crude chalcone-modified triazinepropiconazole product was recrystallized in methanol and dried at 40 °C for 10 h to obtain chalcone-modified triazinepropiconazole, as shown below. Figure 3 As shown.
[0054] Example 2
[0055] like Figure 1 As shown, a chalcone-modified triazinepropiconazole is prepared by a method comprising:
[0056] Step S1: Disperse 10 g of triazinic acid and 5.5 g of chalcone in 40 g of glacial acetic acid, add 25 g of ammonium acetate, react at 110 °C for 7 h to obtain the first intermediate reaction solution, add 80 g of ammonia and 80 g of water, filter to obtain the crude product of the first intermediate, wash the crude product of the first intermediate with ammonia and water respectively, and dry at 70 °C for 9 h to obtain the first intermediate.
[0057] Step S2: 10 g of the first intermediate and 13 g of 1,4-dibromobutane were mixed and added to 40 g of dimethyl sulfoxide. 3 g of potassium carbonate was added, and the mixture was reacted at 90°C for 5 h. The mixture was filtered to obtain the crude product of the second intermediate. The crude product of the second intermediate was washed with water and dried at 55°C for 9 h to obtain the second intermediate, as shown below. Figure 1 As shown.
[0058] Step S3: 10 g of propiconazole was dispersed in 25 g of dimethyl sulfoxide, and 2 g of potassium hydroxide aqueous solution (0.52 g potassium hydroxide and 1.48 g water) was added. The mixture was reacted at 90 °C for 4 h to obtain the crude product of the third intermediate. The crude product of the third intermediate was subjected to column chromatography with a mixture of 750 mL petroleum ether and 100 mL ethyl acetate as the mobile phase, and then dried at 50 °C for 9 h to obtain the third intermediate, as shown below. Figure 2 As shown.
[0059] Step S4: 10 g of the second intermediate and 5.5 g of the third intermediate were dispersed in 40 g of dimethyl sulfoxide, and 3 g of potassium hydroxide was added. The mixture was reacted at 90 °C for 6 h to obtain a crude chalcone-modified triazinepropiconazole product. The crude chalcone-modified triazinepropiconazole product was recrystallized in methanol and dried at 45 °C for 9 h to obtain chalcone-modified triazinepropiconazole, as shown below. Figure 3 As shown.
[0060] Example 3
[0061] like Figure 1 As shown, a chalcone-modified triazinepropiconazole is prepared by a method comprising:
[0062] Step S1: Disperse 10 g of triazinic acid and 6.5 g of chalcone in 50 g of glacial acetic acid, add 30 g of ammonium acetate, react at 120 °C for 6 h to obtain the first intermediate reaction solution, add 150 g of ammonia and 150 g of water, filter to obtain the crude product of the first intermediate, wash the crude product of the first intermediate with ammonia and water respectively, and dry at 60 °C for 8 h to obtain the first intermediate.
[0063] Step S2: 10 g of the first intermediate and 15 g of 1,4-dibromobutane were mixed and added to 50 g of N,N'-dimethylformamide. 5 g of sodium bicarbonate was added, and the mixture was reacted at 100°C for 4 h. The mixture was filtered to obtain the crude product of the second intermediate. The crude product of the second intermediate was washed with water and dried at 60°C for 8 h to obtain the second intermediate, as shown below. Figure 1 As shown.
[0064] Step S3: 10 g of propiconazole was dispersed in 30 g of N,N'-dimethylformamide, and 3 g of sodium hydroxide aqueous solution (1 g sodium hydroxide and 2 g water) was added. The mixture was reacted at 100 °C for 4 h to obtain the crude product of the third intermediate. The crude product of the third intermediate was subjected to column chromatography with a mixture of 800 mL petroleum ether and 100 mL ethyl acetate as the mobile phase, and then dried at 60 °C for 10 h to obtain the third intermediate, as shown below. Figure 2 As shown.
[0065] Step S4: 10 g of the second intermediate and 6 g of the third intermediate were dispersed in 50 g of N,N'-dimethylformamide, and 5 g of triethylamine were added. The mixture was reacted at 100 °C for 5 h to obtain a crude chalcone-modified triazinepropiconazole product. The crude chalcone-modified triazinepropiconazole product was recrystallized in methanol and dried at 50 °C for 8 h to obtain chalcone-modified triazinepropiconazole, as shown below. Figure 3 As shown.
[0066] Comparative Example 1 is unmodified propiconazole.
[0067] Activity testing:
[0068] (1) Compounds from Examples 1 to 3 and Comparative Example 1 were prepared into solutions of 5 mg / kg (solvent being an aqueous ethanol solution); the test site was a paddy field with moderate disease severity and moderate soil fertility, and parallel skip sampling was used, with each plot being 20 m². 2 Five points were set up in each area, and 50 connected rice plants were surveyed at each point. The number of rice plants with sheath blight in each sample point was investigated and recorded in a graded manner.
[0069] (2) The compounds of Examples 1-3 and Comparative Example 1 were prepared into solutions of 5 mg / kg (the solvent was an aqueous ethanol solution). The test site was a wheat field with moderate disease severity and moderate soil fertility. Parallel skip sampling was used, with each plot being 20m².2 Five sampling points were set up in each area, and 50 connected wheat plants were surveyed at each sampling point. The number of wheat plants with sheath blight in the sampling points was investigated and recorded in a graded manner. The positive control group consisted of jinggangmycin and propiconazole.
[0070] (3) Antibacterial activity: The minimum inhibitory concentration (MIC) of the complex against Rhizoctonia graminearum and Rhizoctonia solani was determined by microdilution method, and the minimum bactericidal concentration (MBC) of the complex was determined by PDA solid medium to evaluate the antibacterial activity of the complex.
[0071] Test method: A single isolated colony was taken from PDA solid medium and placed in 5 mL of PDA liquid medium, and incubated overnight at 25°C in a shaker. The overnight culture was diluted with fresh PDA culture medium, and the culture was continued at 25°C in a shaker for 4 h. The bacterial suspension was then diluted to 1×10⁻⁶. 8 CFU / mL.
[0072] The compounds in Examples 1-3 and Comparative Example 1 were prepared into stock solutions (solvent dimethyl sulfoxide) with a concentration of 5 mg / mL. The MIC was determined using a 96-well plate. In each well, the drug was serially diluted with water containing bacterial suspension and solvent (200 µg / mL, 100 µg / mL, 50 µg / mL, 25 µg / mL, 12.5 µg / mL, 6.25 µg / mL, 3.12 µg / mL, 1.56 µg / mL, 0.78 µg / mL, 0.39 µg / mL, 0.2 µg / mL, 0.1 µg / mL). Finally, the 96-well plate was placed in a constant temperature incubator at 25°C for 12 h, and the turbidity of the plate was observed.
[0073] Take the empty portions of the mixture before and after the MIC wells (1 / 2 MIC, MIC, 2 MIC, 4 MIC, 8 MIC, 16 MIC) and spread them evenly on PDA solid medium. Incubate at 25°C for 18 hours and observe the colony growth. All equipment and instruments used were sterile, and all culture media and glassware were autoclaved.
[0074] (4) HC 50 Assay method: Red blood cells were extracted from fresh sterile rabbit blood. The fresh sterile rabbit blood red blood cells were washed with sterile PBS. The analyte was prepared into a test solution of a certain concentration. Then, 50 μL of rabbit blood cells and 150 μL of test solution were added to 1 mL of PBS buffer to make the final concentration of the analyte 250 µg·mL. -1 The mixture was then incubated at 37°C for 30 minutes, centrifuged, and the supernatant was collected. Hemolytic activity was determined by measuring the absorbance at 543 nm. TriX-100 was used as a positive control, and the PBS group as a negative control. The hemolysis rate was calculated. HC 50Defined as the lowest concentration of a compound that causes hemolysis of 50% of blood cells. The test was independently repeated at least three times.
[0075] Table 1. Disease control effect of rice sheath blight
[0076]
[0077] According to the data in Table 1, the microemulsions prepared in Examples 1-3 showed a control efficacy of over 85% against rice sheath blight, and the microemulsions prepared in Examples 1-3 showed a control efficacy of over 75% against rice sheath blight. The average panicle length of rice treated with the solutions from Examples 1-3 was over 15 cm, and the total number of grains per panicle was over 100, demonstrating good activity. The average panicle length of rice treated with the solution from Comparative Example 1 was 12.53 cm, and the total number of grains per panicle was 85, significantly lower than that of Examples 1-3.
[0078] Experiments have shown that propiconazole modified with triazinon via chalcone is more effective in controlling rice stripe disease than unmodified propiconazole, and has less impact on crops.
[0079] Table 2. Disease control effect against wheat sheath blight
[0080]
[0081] According to Table 2, the microemulsions prepared in Examples 1 to 3 have a control efficacy of over 80% against wheat sheath blight. The average spike length of wheat sprayed with the solutions of Examples 1 to 3 is over 10 cm and the average total number of grains per spike is over 45. The average spike length of wheat sprayed with the solution of Comparative Example 1 is 8.28 cm and the average total number of grains per spike is 33, which is significantly lower than that of Examples 1 to 3.
[0082] Experiments have shown that propiconazole modified with triazinon via chalcone is more effective in controlling wheat stripe disease than unmodified propiconazole, and has less impact on crops.
[0083] Table 3. Test data on activity against Rhizoctonia solani.
[0084]
[0085] As shown in Table 3, the compounds prepared in Examples 1-3 all exhibited good inhibitory activity against Rhizoctonia graminearum, and their antibacterial and bactericidal effects were significantly higher than those in Comparative Example 1. Among them, the compound prepared in Example 2 showed the best activity, with a MIC of 1.5625 μg / mL and an MBC of 25 μg / mL. The experiment demonstrated that modifying the structure of propiconazole can improve its inhibitory ability against Rhizoctonia graminearum.
[0086] HC of the compounds prepared in Examples 1-3 50 The values were all greater than 200 μg / mL, indicating that it exhibits low toxicity to mammals. Comparative Example 1 showed some toxicity.
[0087] Table 4. Data on activity against Rhizoctonia solani.
[0088]
[0089] MIC is the minimum inhibitory concentration; MBC is the minimum bactericidal concentration; HC 50 The drug concentration required to destroy 50% of sterile defibrinated rabbit blood cells.
[0090] As shown in Table 4, the compounds prepared in Examples 1-3 exhibited good inhibitory activity against Rhizoctonia solani, with the MIC values for Examples 1 and 2 being 1.5625 μg / mL and HC... 50 The MIC value was greater than 200 μg / mL, while the MIC value of Comparative Example 1 was 100 μg / mL, significantly higher than the compounds prepared in Examples 1-3, and exhibited higher toxicity to mammals. Experiments demonstrated that modifying the structure of propiconazole could improve its inhibitory effect on Rhizoctonia solani, and the modified structure showed low toxicity to mammals.
[0091] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the technical principles of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.
Claims
1. A chalcone-modified triazinepropiconazole, characterized in that, The structure of the chalcone-modified triazinepropiconazole is shown below: 。 2. The method for preparing chalcone-modified triazinepropiconazole according to claim 1, characterized in that, include: Step S1: Disperse triazinon acid and chalcone in glacial acetic acid, add ammonium acetate, react to obtain the first intermediate reaction solution, add ammonia and water, filter to obtain the crude product of the first intermediate, wash and dry the crude product of the first intermediate to obtain the first intermediate; Step S2: The first intermediate is mixed with 1,4-dibromobutane and added to a solvent. A neutralizing agent is added, and the mixture is reacted and filtered to obtain the crude product of the second intermediate. The crude product of the second intermediate is washed and dried to obtain the second intermediate. Step S3: Disperse propiconazole in a solvent, add an alkaline solution, and react to obtain the crude product of the third intermediate. After column chromatography and drying, the crude product of the third intermediate is obtained. In step S4, the second and third intermediates are dispersed in a solvent, a catalyst is added, and the reaction yields a crude product of chalcone-modified triazinepropiconazole. After recrystallization and drying, the crude product of chalcone-modified triazinepropiconazole is obtained.
3. The method for preparing chalcone-modified triazinepropiconazole according to claim 2, characterized in that, In step S1, the reaction temperature is 100~120℃, the reaction time is 6~8 h, the amount of ammonia added is 1~3 times the mass of the solvent, the amount of water added is 1~1.5 times the mass of the ammonia, the washing solvent is ammonia and water, the drying temperature is 60~70℃, and the drying time is 8~10 h.
4. The method for preparing chalcone-modified triazinepropiconazole according to claim 2, characterized in that, In step S1, the mass ratio of triazinic acid, chalcone, ammonium acetate, and solvent is 1:(0.45~0.65):(2~3):(3~5).
5. The method for preparing chalcone-modified triazinepropiconazole according to claim 2, characterized in that, The solvent is any one or more of N,N'-dimethylformamide and dimethyl sulfoxide; in step S2, the neutralizing agent is any one or more of sodium bicarbonate and potassium carbonate; the reaction temperature is 80~100℃, and the reaction time is 4~6h.
6. The method for preparing chalcone-modified triazinepropiconazole according to claim 2, characterized in that, In step S2, the mass ratio of the first intermediate, 1,4-dibromobutane, neutralizing agent, and solvent is 1:(1.1~1.5):(0.1~0.5):(3~5); the drying temperature is 50~60℃, and the drying time is 8~10 h.
7. The method for preparing chalcone-modified triazinepropiconazole according to claim 2, characterized in that, In step S3, the alkaline solution is any one or more of sodium hydroxide aqueous solution and potassium hydroxide aqueous solution, wherein the mass ratio of water to sodium hydroxide in the sodium hydroxide aqueous solution is 1:(0.15~0.5), and the mass ratio of water to potassium hydroxide in the potassium hydroxide aqueous solution is 1:(0.15~0.5).
8. The method for preparing chalcone-modified triazinepropiconazole according to claim 2, characterized in that, In step S3, the mass ratio of propiconazole, alkaline solution, and solvent is 1:(0.1~0.3):(2~3); the reaction temperature is 80~100℃, and the reaction time is 4~5 h; the mobile phase for column chromatography is petroleum ether and ethyl acetate, and the volume ratio of petroleum ether to ethyl acetate is (5~8):1; the drying temperature is 50~60℃, and the drying time is 8~10 h.
9. The method for preparing chalcone-modified triazinepropiconazole according to claim 2, characterized in that, In step S4, the catalyst is any one or more of sodium hydroxide, potassium hydroxide, and triethylamine; the mass ratio of the second intermediate, the third intermediate, the catalyst, and the solvent is 1:(0.5~0.6):(0.2~0.5):(3~5); the recrystallization solvent is methanol; the reaction temperature is 80~100℃, the reaction time is 5~8 h; the drying temperature is 40~50℃, and the drying time is 8~10 h.
10. The use of a chalcone-modified triazinepropiconazole according to claim 1 in a bactericidal agent.
Citation Information
Patent Citations
Propiconazole-like compound, and preparation method and application thereof
CN113234066A
Propiconazol metal complex, preparation method and use thereof
CN1923838A
